Large
Degree of Innovation in Parkinson's Disease Pipeline
The Parkinson's disease (PD)
pipeline currently has 302 products in active development across all stages,
but a stark contrast between the mechanisms of action employed in the current
market and the pipeline is evident. Where the market relies on symptomatic
treatments that target neuromodulatory receptors, the pipeline shows a diverse
range of neuroprotective therapies targeting dysfunctional disease processes.
This diversity is partially due
to the presence of 90 first-in-class products, which accounts for 37% of the
overall pipeline therapies that disclosed their target. In an industry, market
and development landscape that favors first-in-class over non-first-in-class
development in many ways, such as through faster approval or greater revenue,
this finding has strategic implications for a wide array of market
participants, both large and small.
Despite their historically high
attrition rate, first-in-class therapies that reach the market have the
potential to transform and improve the PD treatment landscape.
View
Full Report with TOC @ http://www.radiantinsights.com/research/frontier-pharma-parkinson-s-disease-identifying-and-commercializing-first-in-class-innovation
Alignment
of First-in-Class Molecular Target with Disease Processes and Genetics
PD is a complex and multifaceted
disease with a complex interplay between different pathological processes.
Enormous research efforts and significant technological advances have furthered
knowledge of the neuroanatomy of the basal ganglia and of the fundamental
processes underlying neurodegeneration, helped by the ongoing identification of
susceptibility genes and causative genes in familial PD.
Although the exact mechanisms
that initiate onset remain unclear, these insights have been translated into
the pool of novel therapeutic targets, which may potentially become
disease-modifying therapies by aligning to the disease processes and some
genetic determinants of PD.
GBI Research's proprietary
analysis showed substantial variation in how well the functional roles of PD
first-in-class targets align to the pathophysiology of PD. Further in-depth
analysis identified the most promising first-in-class targets based on various
scientific and clinical parameters.
Examining scientific and clinical
data of promising first-in-class targets showed that first-in-class status is
not, in its own right, enough for a successful product; however, the
first-in-class products substantiated by scientific and clinical evidence will
be exciting future prospects with the potential to transform the PD market.
First-in-Class
Products in Licensing and Co-development Deals
Strategic consolidation is
relatively uncommon in the PD market. Concerning first-in-class specifically,
only nine first-in-class products that are currently in development have been
involved in licensing or co-development deals since 2006. Despite the low
sample size, it is clear that the first-in-class PD products offer an
attractive investment prospect as they command much higher deal values and, on
average, deals occur earlier in development compared to non-first-in-class
counterparts.
Both trends were substantiated by
industry-wide data that showed that, particularly in Phase I, first-in-class
products would attract larger mean and median total deal values. The data
highlight that the first-in-class deals landscape is different and indicates a
greater chance of becoming much more lucrative than the deals landscape for
addition-to-class or advance-in-class therapies.
A total of 81 first-in-class
products that are currently in development have not yet been entered into a
licensing or co-development deal. Under a growing unmet need for
disease-modifying therapies and increasing understanding of disease processes
allowed by technological advances, there are numerous opportunities for
strategic alliances to bolster a first-in-class portfolio or fund clinical
development. Some of these first-in-class products are supported by promising
scientific and clinical data, making them attractive prospects as both
therapeutics and investment opportunities.
Scope
The report analyzes innovation in
PD in the context of the overall pipeline and current market landscape. It also
analyzes the deals landscape surrounding first-in-class products and pinpoints
in-licensing opportunities.The report includes -
- A brief introduction to PD,
including symptoms, pathophysiology, and an overview of pharmacotherapy and
treatment algorithms
- Coverage of the changing
molecular target landscape and particular points of innovation in the pipeline
- A comprehensive review of the
pipeline for first-in-class therapies, analyzed by stage of development,
molecule type and molecular target
- Identification and assessment
of first-in-class molecular targets with a particular focus on early-stage
programs of which clinical utility has yet to be evaluated, as well as
literature reviews of novel molecular targets
- Industry-wide analysis of
first-in-class deals compared to non-first-in-class deals
- An assessment of the licensing
and co-development deal landscape for PD therapies and benchmarking of deals
comparing first-in-class and non-first-in-class-products
Reasons
to buy
The report will enable business
development and enable marketing executives to strategize their product
launches by allowing them to -
- Understand the focal shifts in
molecular targets in the PD pipeline
- Understand the distribution of
pipeline programs by phase of development, molecule type and molecular target
- Access a scientific and
clinical analysis of first-in-class developmental programs for PD, benchmarked
against non-first-in-class targets
- Assess the valuations of
licensed and co-developed PD treatments
- Access a list of the
first-in-class therapies potentially open to deal-making opportunities
About
Us
Radiant Insights is a platform
for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog
URL: http://www.esorics2010.org/
No comments:
Post a Comment